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Objectives: To quantify the prevalence of neurological complications among breast cancer patients at one
and three years after diagnosis, and to identify factors associated with neuropathic pain (NP) and
chemotherapy-induced peripheral neuropathy (CIPN).
Material and methods: Prospective cohort study including 475 patients with newly diagnosed breast
cancer, recruited among those proposed for surgical treatment (Portuguese Institute of Oncology, Porto).
Patients underwent a neurological evaluation and had their cognitive function assesses with the Mon-
treal Cognitive Assessment, before treatment and at one and three years after enrollment. We estimated
the prevalence of each neurological complication, and odds ratios (OR), adjusted for socio-demographic
and clinical characteristics, to identify factors associated with NP and CIPN.
Results: More than half of the patients [54.7%, 95% conﬁdence interval (95%CI): 50.2e59.2] presented at
least one neurological complication, at one or at three years after cancer diagnosis. Between the ﬁrst and
the third year of follow-up, there was an increase in the prevalence of NP (from 21.1% to 23.6%), cognitive
impairment (from 7.2% to 8.2%), cerebrovascular disease (from 0.6% to 1.5%) and brain metastasis (from
0.0% to 0.6%). The prevalence of CIPN decreased from 14.1% to 12.6%. Axillary lymph node dissection was
associated with NP at one year (OR ¼ 2.75, 95%CI: 1.34e5.63) and chemotherapy with NP at three years
(OR ¼ 2.10, 95%CI: 1.20e3.67). Taxane-based chemotherapy was strongly associated with prevalence of
CIPN at one and three years.
Conclusion: Neurological complications are frequent even three years after cancer diagnosis and NP
remained the major contributor to the burden of these conditions among survivors.
© 2016 Published by Elsevier Ltd.Introduction
Breast cancer is the most frequent cancer among women, esti-
mated to have accounted for approximately one quarter of all cases
of cancer diagnosed in 2012 [1]. Access to early diagnosis through
mammography screening and effective treatments [2] makes
breast cancer one of those with a better prognosis. The 5-year net
survival is now greater than 80% in most developed countries [3],l Epidemiology, Predictive
niversity of Porto, Al. Prof.
51 225513652.and this translates into a high number of women living for longer
periods with possible sequelae of breast cancer and its treatment,
emphasizing the relevance of a comprehensive study of the burden
of cancer among survivors.
Neurological complications, either direct, namely metastatic
disease, or due to indirect mechanisms, including vascular disor-
ders, paraneoplastic syndromes or side-effects of treatments, may
be a frequent source of morbidity among breast cancer patients
[4,5]. We previously followed a cohort of breast cancer patients
during the ﬁrst year after diagnosis, and showed that nearly half of
the women treated for breast cancer had at least one neuro-
oncological complication and one quarter developed at least two
during this period; the most frequent were neuropathic pain (NP)
and chemotherapy-induced peripheral neuropathy (CIPN) [6].
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additional treatments, the late and/or cumulative effects of some
options of cancer management, but also the possibility of recov-
ering from some of the neuro-oncological complications over time,
bring attention to the importance of a comprehensive assessment
of the prevalence of these conditions in the long term. Therefore,
we updated the follow-up of this cohort up to three years after
diagnosis, aiming to quantify the prevalence of neurological com-
plications among breast cancer patients, and to identify factors
associated with NP and CIPN.
Material and methods
We conducted a prospective study with newly diagnosed breast
cancer women, followed for three years. The study protocol has
been described in detail elsewhere [7].
Patients and setting
Patients proposed for surgery were consecutively recruited in
2012, among those admitted to the Breast Clinic of the Portuguese
Institute of Oncology of Porto, Portugal. We excluded women that
had received any treatment for breast cancer before, those previ-
ously treated with chemotherapy and/or radiotherapy in the chest
and/or axillary areas for other primary cancers, and those consid-
ered less likely to be able to cooperate due to cognitive impairment
[score lower than 17, or lower than 16 for women over 65 years, in
the Montreal Cognitive Assessment (MoCA) [8,9]].
The cohort included 506 patients with incident breast cancer,
fromwhom 31were lost to follow-up until the three-year of follow-
up (11 patients died, 10 abandoned the study, six could not be
contacted, two were transferred to another hospital and two were
considered unable to cooperate by the neurologist). Therefore, a
total of 475 (93.9%) completed the three-year follow-up evaluation
with a median [percentile 25-percentile 75 (P25-P75)] time of
follow-up of 1095 (1073e1126) days and were included in the
present analysis. The patients lost to follow-up were not signiﬁ-
cantly different (participants vs. lost to follow-up) regarding age
(median: 54.7 vs. 58.1 years, p ¼ 0.130), education [median: 6 vs. 4
schooling years (4e6), p ¼ 0.081] and cancer stage (stage 0/I: 53.9%
vs. 48.4%, p ¼ 0.581).
Data collection
All participants underwent a neurological evaluation at baseline
(before any treatment) and at one and three years after enrollment.
Complementary exams (e.g.: computed tomography, magnetic
resonance imaging, nerve conducting studies) were requested
whenever indicated, according to the usual practice of the hospital.
In all evaluations, socio-demographic data were collected using a
structured questionnaire and clinical records were reviewed for
cancer stage, breast cancer treatments and the presence of recur-
rence. Cancer stage was classiﬁed according to the American Joint
Committee on Cancer staging manual [10].
Prevalence of neurological complications
Neurological complications affecting the patients at one and
three years after cancer diagnosis were recorded; this included
conditions identiﬁed de novo in any of these follow-up evaluations
or diagnosed before, but still present at the follow-up evaluation.
CIPN was deﬁned as peripheral neuropathy occurring after
chemotherapy. Among subjects with peripheral neuropathy at
baseline, CIPN was considered present only if there was a wors-
ening of the preexisting neuropathy. The severity of CIPN wasquantiﬁed using the Total Neuropathy Score, clinical version (TNSc)
(range: 0 to 28) [11] and the Common Terminology Criteria for
Adverse Events, V.4.0 (CTCAE) (range: 1 to 5) [12]. In both scales,
higher scores represent greater severity.
NP was considered probable, according to the International
Association for the Study of Pain (IASP) [13], if pain distributionwas
neuroanatomically plausible and history was suggestive of relevant
lesions or diseases affecting the somatosensory system, plus
negative or positive sensory signs in neurological examination,
conﬁned to the innervation territory of the injured nervous struc-
ture. Pain sensation and light touch sensationwere assessed using a
wood cocktail stick and a piece of cotton wool, respectively, as
recommended by the IASP [13]. We considered NP secondary to
breast cancer treatments as prevalent in each of the evaluations if it
was present in the last 24 h, in the breast, chest wall, axilla, or
medial upper arm on the affected side, donor region of breast
reconstruction, or in the hands/feet (secondary to CIPN). In order to
quantify pain severity, the severity subscale of the Brief Pain In-
ventory Short Form was used [14]; it consists of a mean score of
four questions measuring the worst, least, average and current pain
in the past 24 h (range: 0 to 10, with 0¼ “no pain” and 10¼ “pain as
bad as you can imagine”).
Among patients submitted to mastectomy, phantom breast
syndrome was deﬁned as the presence of the sensation that the
removed breast is still present [15]. When in addition, patients
described a sensation of pain in the removed breast, phantom
breast painwas considered present [15] and the CTCAE was used to
grade phantom pain (range: 1 to 5) [12].
Cognitive impairment was considered present when the pa-
tients' MoCA score (range: 0 to 30) was at least 2.0 standard de-
viations below age- and education-adjusted cut-offs for possible
cognitive impairment [8].
Statistical analysis
Patients' characteristics were presented as counts and pro-
portions for all categorical variables, and median and P25-P75 for
quantitative variables.
Prevalence estimates and corresponding 95% conﬁdence in-
tervals (95%CI) were estimated for each of the neurological com-
plications at one and three years after cancer diagnosis. The
McNemar's test was used to compare the proportion of patients
with each complication at one and three years.
Adjusted odds ratios (OR) and 95%CI were computed using lo-
gistic regression, to quantify the relation between sociodemo-
graphic and clinical characteristics of the patients and the presence
of NP and CIPN at one and three years after cancer diagnosis.
Statistical analyses were conducted using STATA®, version 11.2
(StataCorp, College Station, TX, USA).
Results
Patients' characteristics
At baseline, half of the women had less than 55 years of age and
more than two thirds had less than 10 years of education. A total of
6.5% were diagnosed with non-invasive breast cancer (ductal car-
cinoma in situ) and the remaining with invasive breast cancer stage
I (47.4%), II (30.7%), III (14.7%) or IV (0.6%).
The breast cancer treatments performed during the ﬁrst year
after diagnosis are presented in Table 1. Nearly half of the patients
were submitted to mastectomy and just over one third to axillary
lymph node dissection (ALND). Most of the participants underwent
adjuvant treatment. Docetaxel-based regimens were used by more
than two thirds of women receiving chemotherapy.
Table 1
Breast cancer treatments performed during the ﬁrst year after diagnosis (N ¼ 475).
N (%)
Breast surgerya
Mastectomy 220 (46.3)
Mastectomy þ breast-reconstruction 15 (3.2)
Breast-conserving 239 (50.3)
Axillary surgeryb
Lymph node dissection 162 (34.1)
Sentinel lymph node biopsy 299 (62.9)
Chemotherapy 288 (60.6)
Timingc
Neoadjuvant 32 (11.1)
Adjuvant 256 (88.9)
Drugsc
Doxorubicin þ cyclophosphamide 59 (20.5)
Doxorubicin þ cyclophosphamide þ docetaxel 30 (10.4)
Doxorubicin þ cyclophosphamide þ paclitaxel 1 (0.4)
Cyclophosphamide þ docetaxel 2 (0.7)
Carboplatin þ docetaxel 1 (0.4)
5-FU þ epirubicin þ cyclophosphamide 23 (8.0)
5-FU þ epirubicin þ cyclophosphamide þ docetaxel 171 (59.4)
5-FU þ cyclophosphamide þ methotrexate 1 (0.4)
Radiotherapy (chest, axillary and/or supraclavicular) 350 (73.7)
Brachytherapy 91 (19.2)
Endocrine therapyd 400 (84.2)
Immunotherapyd 63 (13.3)
5-FU, 5-Fluorouracil.
a Patients who had both mastectomy and breast-conserving surgery are reported
as mastectomy. Does not sum 100.0% because one patient only performed axillary
surgery.
b Patients who had both lymph node dissection and sentinel lymph node biopsy
are reported as lymph node dissection. Does not sum 100.0% because 14 patients
only performed breast surgery.
c Only computed among those who performed chemotherapy.
d All patients began this treatment during the ﬁrst year of follow-up and
remained under treatment after the one-year follow-up evaluation.
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the patients underwent each of the following treatments: ALND,
metastasectomy, radiotherapy or chemotherapy (Table 2).Prevalence of neurological complications at one and three years of
follow-up
Just over 40% of breast cancer patients had at least one cancer-
related neurological complication, at one (42.7%, 95%CI:Table 2
Cancer treatments performed after the ﬁrst year after diagnosis (N ¼ 475).
N (%)
Breast surgery
Breast-reconstruction 26 (5.5)
Axillary surgery
Lymph node dissection 1 (0.2)
Hepatic metastasectomy 1 (0.2)
Cerebral metastasectomy 1 (0.2)
Chemotherapy 9 (1.9)a
Drugsb
Capecitabine 3 (33.3)
Docetaxel 2 (22.2)
Paclitaxel 5 (55.6)
Vinorelbine 1 (11.1)
Rituximab þ cyclophosphamide þ doxorubicin þ vincristine 1 (11.1)c
Radiotherapy (chest, axillary, supraclavicular,
bone and/or cerebral)
7 (1.5)
a Only one of these patients was not submitted to chemotherapy during the ﬁrst
year of follow-up.
b Only computed among those who performed chemotherapy. Does not sum
100.0% because some patients were submitted to more than one scheme after the
ﬁrst year after diagnosis.
c Patient submitted to chemotherapy due to a second primary cancer.38.4e47.2) and three years of follow-up (41.7%, 95%CI: 37.3e46.2).
More than half of the participants (54.7%, 95%CI: 50.2e59.2) pre-
sented at least one neurological complication, either at one- or at
three-year follow-up evaluation.
As depicted in Fig. 1, between the ﬁrst and the third year after
breast cancer diagnosis, there was a non-statistically signiﬁcant
increase in the prevalence of NP, from 21.1% to 23.6% (p ¼ 0.225),
and a signiﬁcant decrease in the proportion of women with
phantom breast syndrome, from 17.1% to 10.7% (p < 0.001). The
prevalence of cognitive impairment varied from 7.2% to 8.2%
(p ¼ 0.466), though 55.9% and 28.2% of those with cognitive
impairment at one and three years, respectively, already presented
this condition prior to treatment. The variation in the prevalence of
cerebrovascular disease (from 0.6% to 1.5%; p ¼ 0.125) and CIPN
(from 14.1% to 12.6%; p ¼ 0.127) was not statistically signiﬁcant.
Brain metastasis were identiﬁed in three patients (0.6%, 95%CI:
0.1e1.9) at the three-year evaluation.
The association between different characteristics of the patients
and the presence of NP at one and three years after cancer diagnosis
are reported in Table 3. At one year, older patients were less likely to
present NP and those with cancer stage III/IV and those who un-
derwent ALND presented higher odds of NP. At three years after
cancer diagnosis only the patients submitted to chemotherapy had
higher odds of NP. Those with NP at one year after cancer diagnosis
had eight fold higher odds of NP at three years (OR ¼ 8.20, 95%CI:
4.84e13.9, adjusted for all variables presented in Table 3).
The association between different characteristics of the pa-
tients and the presence of CIPN at one and three years after cancer
diagnosis are reported in Table 4. Cancer stage III/IV and taxane-
based chemotherapy were associated with a higher odds of
CIPN, both at one and three years. Patients undergoing chemo-
therapy between the ﬁrst and the third year had higher odds of
CIPN at the three-year follow-up than those treated with
chemotherapy only during the ﬁrst year (OR ¼ 11.7, 95%CI:
2.16e63.89, adjusted for all variables presented in Table 4).
Fig. 2 depicts the number of patients with the most common
neurological complications, according to their presence at one and
three years of follow-up. More than three quarters of the women
with CIPN and more than half of those with NP remained affected
by these conditions three years after cancer diagnosis. A total of
66.7% of the patients presenting cognitive impairment and 49.1% of
those with NP at the three-year follow-up were not prevalent cases
at the one-year evaluation.
Pain severity scores among patients with NP are presented in
Fig. 3. Among those with NP in both moments there was a signiﬁ-
cant increase in the median score (2.4 vs. 3.2, p < 0.005). NP was
less severe amongwomenpresenting this condition at the one-year
evaluation only, than those with NP at the three-year follow-up
only (median score: 1.2 vs. 2.5, p < 0.001).
Among those with CIPN in both moments, there was a signif-
icant decrease in the median score of TNSc (5.0 vs. 4.0, p ¼ 0.006).
CIPN had greater severity among women presenting this condi-
tion at the three-year evaluation only, than those with CIPN at the
one-year follow-up only (median score: 10.0 vs. 1.5, p < 0.005)
(Fig. 4).
According to the CTCAE, in patients with CIPN at both moments
of follow-up, almost all presented peripheral sensory neuropathy
grade 1 or 2 (100.0% at the one- and 98.1% at the three-year
follow-up); motor symptoms (grade 1 to 3) were much less
frequent (7.6% at the one- and 15.1% at the three-year follow-up).
Among womenwith CIPN at only the one-year or at the three-year
follow-up evaluation, the prevalence of sensory neuropathy
(grade 1 to 3) was 92.9% and 100.0%, respectively, and the pro-
portion of patients with motor neuropathy (grade 1) was 7.1% and
57.1%, respectively.
Fig. 1. Prevalence of neurological complications at one and three years after diagnosis (N ¼ 475). CIPN, Chemotherapy-induced peripheral neuropathy; NP, Neuropathic pain. aA total
of 29.6% and 29.4% of the patients with phantom breast syndrome at one and three years, respectively, experienced painful sensations and were classiﬁed as cases of phantom breast
pain grade 1, according to the Common Terminology Criteria for Adverse Events, V.4.0. The prevalence of phantom breast syndrome among women who underwent mastectomy
without reconstruction was 36.4% (95%CI: 30.3e42.9) at one year and 26.3% (95%CI: 20.6e32.9) at three years (p < 0.001). bAmong the patients undergoing chemotherapy, the
prevalence of CIPN was 23.3% (95%CI: 18.7e28.5) and 20.5% (95%CI: 16.2e25.5) at one and three years (p ¼ 0.074), respectively.
Table 3
Association between sociodemographic and clinical characteristics of the patients and NP at one and three years after cancer diagnosis (N ¼ 475).
Neuropathic pain at one year Neuropathic pain at three years
Patients with NP [N (%)] Adjusted OR (95%CI) Patients with NP [N (%)] Adjusted OR (95%CI)
Age (years)
55 61 (25.3) 1 (ref.) 64 (26.6) 1 (ref.)
>55 39 (16.7) 0.59 (0.38e0.93) 48 (20.5) 0.71 (0.47e1.09)
Education (years)
4 40 (20.0) 1 (ref.) 51 (25.5) 1 (ref.)
5e9 29 (21.5) 0.86 (0.48e1.53)c 28 (20.7) 0.62 (0.35e1.08)c
10 31 (22.1) 0.87 (0.49e1.55)c 33 (25.6) 0.71 (0.41e1.24)c
Cancer stage at baseline
0/I 40 (15.6) 1 (ref.) 53 (20.7) 1 (ref.)
II 29 (19.9) 1.30 (0.76e2.22)d 36 (24.7) 1.27 (0.78e2.07)d
III/IV 31 (42.5) 3.83 (2.13e6.86)d 23 (31.5) 1.75 (0.97e3.16)d
Breast surgerya (N ¼ 474)
Breast-conserving 39 (16.3) 1 (ref.) 53 (22.2) 1 (ref.)
Mastectomy 61 (26.0) 1.33 (0.82e2.17)e 59 (25.1) 1.01 (0.64e1.60)e
Axillary surgeryb (N ¼ 461)
SLNB 44 (14.7) 1 (ref.) 58 (19.5) 1 (ref.)
ALND 56 (34.6) 2.75 (1.34e5.63)e 49 (30.1) 1.59 (0.82e3.07)e
Chemotherapy
No 26 (13.9) 1 (ref.) 30 (16.1) 1 (ref.)
Yes 74 (25.7) 1.47 (0.80e2.70)e 82 (28.4) 2.10 (1.20e3.67)e
Radiotherapy
No 24 (19.2) 1 (ref.) 24 (19.4) 1 (ref.)
Yes 76 (21.7) 0.72 (0.32e1.59)f 88 (25.1) 1.24 (0.58e2.65)f
Brachytherapy
No 89 (23.2) 1 (ref.) 91 (23.7) 1 (ref.)
Yes 11 (12.1) 0.53 (0.24e1.15)f 21 (32.1) 0.93 (0.48e1.82)f
ALND, Axillary lymph node dissection; NP, Neuropathic pain; SLNB, Sentinel lymph node biopsy.
a Patients who had both mastectomy and breast-conserving surgery are reported as mastectomy; N < 475 because one patient only performed axillary surgery.
b Patients who had both ALND and SLNB are reported as ALND; N < 475 because 14 patients only performed breast surgery.
c Adjusted for age.
d Adjusted for age and education.
e Adjusted for age, education and cancer stage.
f Adjusted for age, education, cancer stage, breast and axillary surgery.
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Table 4
Association between sociodemographic and clinical characteristics of the patients and CIPN at one and three years after cancer diagnosis, among those who performed
chemotherapy until the ﬁrst (N ¼ 288) and until the third year of follow-up (N ¼ 289).
CIPN at one year CIPN at three years
Patients with CIPN [N (%)] Adjusted OR (95%CI) Patients with CIPN [N (%)] Adjusted OR (95%CI)
Age (years)
55 39 (22.7) 1 (ref.) 33 (19.2) 1 (ref.)
>55 28 (24.1) 1.09 (0.62e1.89) 27 (23.1) 1.26 (0.71e2.24)
Education (years)
4 22 (22.0) 1 (ref.) 21 (20.8) 1 (ref.)
5-9 21 (21.0) 0.99 (0.49e2.02)a 17 (17.0) 0.87 (0.41e1.83)a
10 24 (27.3) 1.41 (0.69e2.85)a 22 (25.0) 1.42 (0.69e2.93)a
Cancer stage at baseline
0/I 12 (13.2) 1 (ref.) 13 (14.1) 1 (ref.)
II 29 (22.8) 2.01 (0.96e4.22)b 22 (17.3) 1.34 (0.63e2.86)b
III/IV 26 (37.1) 4.12 (1.87e9.06)b 25 (35.7) 3.73 (1.70e8.14)b
5-FU-based chemotherapy
No 5-FU 15 (16.1) (ref.) 16 (17.0) (ref.)
5-FU 52 (26.7) 1.99 (1.00e4.00)c 44 (22.6) 1.65 (0.83e3.30)c
Taxane-based chemotherapy
No taxane 1 (1.20) 1 (ref.) 2 (2.5) 1 (ref.)
Taxane 66 (32.2) 34.59 (4.57e261.96)c 58 (27.9) 14.76 (3.31e65.79)c
CIPN, Chemotherapy-induced peripheral neuropathy; 5-FU, 5-Fluorouracil.
a Adjusted for age.
b Adjusted for age and education.
c Adjusted for age, education and cancer stage.
Fig. 2. Variation of the number of patients with the most common neurological complications, according to its presence at one-year after diagnosis. CI, Cognitive impairment; CIPN,
Chemotherapy-induced peripheral neuropathy; NP, Neuropathic pain; PBS, Phantom breast syndrome.
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Three years after a diagnosis of breast cancer, more than 40% of
the patients presented at least one oncological-related neurological
complication, largely due to conditions that were not observed one
year after cancer diagnosis. During this period, there was an in-
crease in the prevalence of NP, cognitive impairment, cerebrovas-
cular disease and brain metastasis and a decrease in the proportion
of patients with phantom breast syndrome and CIPN, though dif-
ferences were not statistically signiﬁcant except for phantom breast
syndrome and brain metastasis. ALND was associated with NP atone year and chemotherapy with NP at three years. Taxane-based
chemotherapy was strongly associated with prevalence of CIPN at
one and three years.
NP was the most frequent treatment-related complication, both
one and three years after cancer diagnosis. Two recent studies
addressing the frequency of NP in breast cancer patients reported
prevalence estimates close to those observed in our study [16,17];
in a prospective study of women who underwent surgery for pri-
mary breast cancer, Bruce et al. reported a prevalence of 24% of
predominantly NP at nine months, according to the Self-
Administered Leeds Assessment of Neuropathic Symptoms and
Fig. 3. Pain Severity at one- and three-years after cancer diagnosis, among those with NP, according to the moment of evaluation. NP, Neuropathic pain. aPatients with prevalent NP
at one-year after cancer diagnosis had its severity assessed at the diagnosis of NP (within the ﬁrst year of follow-up) and six-months after (if NP was still present); for these patients,
we selected the score obtained at the evaluation closest to the one-year follow-up. bPatients with prevalent NP at the three-year follow-up evaluation had its severity evaluated at
that moment.
Fig. 4. Total neuropathy score at one- and three-years after cancer diagnosis, among those with CIPN, according to the moment of evaluation. CIPN, Chemotherapy-induced pe-
ripheral neuropahy; TNSc, Total Neuropathy score (clinical version). aPatients with prevalent CIPN at one-year after cancer diagnosis had its severity assessed at the diagnosis of
CIPN (within the ﬁrst year of follow-up) and six-months after (if CIPN was still present); for these patients, we selected the score obtained at the evaluation closest to the one-year
follow-up. bPatients with prevalent CIPN at the three-year follow-up evaluation had its severity evaluated at that moment.
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F. Fontes et al. / The Breast 29 (2016) 31e38 37Signs (S-LANSS) or the Neuropathic pain questionnaire (DN4) [16].
In a retrospective study including women treated between two to
six years before, Bredal et al. described the presence of symptoms
and signs of NP in 26% of the participants, according to the S-LANSS
[17].
Even though NP is a frequently recognized complication of
surgical and adjuvant treatments for breast cancer [15,18], there is
scarce information regarding how it evolves in the long term in the
same patients. The fact that signs and symptoms that characterize
NP occur as a dynamic spectrum that is unstable over time [19,20]
could, at least in part, explain our ﬁndings of an increase in its
prevalence during follow-up. Among breast cancer patients, dam-
age of the intercostobrachial nerve, which can occur with ALND,
has been considered the most common source of NP [15] and pa-
tients submitted to chemotherapy may develop NP secondary to
CIPN [18]; our results are in agreement with these ﬁndings.
Our study yielded a prevalence of phantom breast syndrome
similar to those found by previous authors reporting that between
15% and 45% of those submitted to mastectomy were diagnosed
with this complication [21e23]. Recently, Medina et al., reported a
decrease in the prevalence from 45% at six weeks to 18% at two
years after surgery [21], which is a accordance to our ﬁndings of a
decrease over time.
Despite direct comparisons being difﬁcult due to the heteroge-
neous chemotherapeutic schemes performed by patients and the
lack of uniformity in CIPN assessment methods, our observations of
a decrease in the prevalence of CIPN between the ﬁrst and the third
year after diagnosis are consistent with previous studies [24,25]. A
systematic review assessing the prevalence of CIPN over time
yielded prevalence estimates of 60.8% in the ﬁrst month after
chemotherapy, 60.0% at three months and 30.0% at six months or
more [25]. In a more recent study, Eckhoff et al. reported a CIPN
prevalence of 16.2% and 13.6% among breast cancer survivors who
underwent docetaxel based-regimens, 1e1.5 years and 2.0e3.2
years after treatment, respectively [24]. The low number of patients
with CIPN diagnosis at only three years reﬂects the scarce number
of women re-submitted to chemotherapy due to cancer recurrence
and its higher severity when compared to those diagnosed at one-
year may reﬂect the use of more neurotoxic drugs [26]. Also, our
ﬁnding of a higher odds of CIPN in those who underwent taxane-
based chemotherapy is in accordance with previous reports sug-
gesting that both docetaxel and paclitaxel could be an important
source of peripheral neuropathy among those undergoing chemo-
therapy for breast cancer [18,26].
Cognitive impairment has been studied among breast cancer
patients, especially in those submitted to chemotherapy [27e29].
Results from cross-sectional studies suggest a decrease in cognitive
function after chemotherapy but prospective designs show an
improvement in cognition over time after treatment [27e29].
However, the former did not take into account the baseline
cognitive status of patients and the latter may be explained by
learning effects due to evaluations using the same instrument at
different moments. In our study, the long period between the one-
and the three-year follow-up evaluations contributes to overcome
learning effects and may explain the contrast with previous results.
Cerebrovascular disease and brain metastasis have been found
in less than 2% of the participants in our study. The latter has been
describes as the most common direct form of nervous system
involvement by cancer, estimated to affect around 5% of breast
cancer patients, up to ﬁve years after diagnosis [30]; the shorter
follow-up of our cohort and the fact that those not proposed for
surgery were excluded, are probably contributing to our observed
prevalence.
Our study contributes to a comprehensive characterization of
the burden of neurological conditions of breast cancer in the longterm. Its major methodological strengths are the prospective
design with a systematic evaluation of all patients before treat-
ment, one year and three years after breast cancer diagnosis, the
nearly complete follow-up of the patients and the use of stan-
dardized instruments to evaluate cognitive function, and to quan-
tify CIPN and NP severity. However, some limitations need to be
addressed. We excluded those not submitted to surgical treatment,
whichmay limit the generalization to patients with more advanced
disease, where direct complications of breast cancer are expected
to bemore frequent. Finally, most of the neurological complications
had only clinical diagnosis, which limits the accuracy of the infor-
mation regarding these disorders. However, our results are ex-
pected to reﬂect ﬁndings in usual clinical practice, since all patients
were treated according to the usual practice of a major oncological
hospital.
In conclusion, our study shows that neurological complications
are frequent even three years after cancer diagnosis and highlights
the role of NP as a major contributor to the burden of these con-
ditions among survivors.Ethical approval
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